Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03860233
Other study ID # GWU_IRB_031857
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 4, 2019
Est. completion date November 1, 2024

Study information

Verified date January 2023
Source George Washington University
Contact Vivek Jain, MD
Phone 202-741-2237
Email vjain@mfa.gwu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea. This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.


Description:

This is a rigorous randomized, double-blinded, cross-over study. Patients will self-administer either oxytocin nasal spray (40IU/ml), or sterile water spray, for 2 weeks, followed by 2 weeks of the spray not used initially (with a one week washout period in between). Subjects will have been using (for a minimum of 1 month) an auto-adjusting/titrating positive airway pressure (auto-CPAP device) as this is the mainstay of treatment for OSA and considered standard-of-care. All auto-CPAP devices are capable of recording frequency and duration of patient use (thus helping with compliance monitoring) and also recording the pressure needed to keep the airway open. After obtaining consent, forty subjects will undergo the following (at Day 1): (a) venipuncture to obtain 50 ml of blood (to be stored for use to analyze inflammatory markers and biomarkers of oxidative stress, (b) an overnight sleep study in the sleep-lab (with their auto-CPAP) to assess sleep architecture, (c) download of their compliance report from the auto-CPAP to assess mean PAP pressure. They will then be randomized to receive either 40 i.u (1 ml/10 nasal sprays) intranasally of oxytocin per night for 2 weeks (14 days), or matching placebo (1 ml/10 sprays) intranasally per night for 2 weeks (14 days). The researchers and subjects will be blinded to the order of oxytocin versus placebo and to the randomization process (will be done by the MFA-investigational drug pharmacy). The end of the 2 week (14 day) period will mark day 14. Subjects will continue using their auto-CPAP during these 2 weeks as per standard-of-care. At day 14: (a) subjects will undergo another overnight in-lab sleep study (with their auto-CPAP) to assess sleep architecture, and (b) have another venipuncture to collect 50 ml of blood, (c) download of compliance report from their auto-CPAP, and continue to take either the placebo or oxytocin. Each subject will then have a wash-out period of 1 week (Days 14-21, they will continue using their auto-CPAP during this week as per standard-of-care). Beginning at Day 21 each subject will then receive either oxytocin or placebo (the opposite of what they did not receive the first time at point A) for 14 days (2 weeks) Days 21-35: nightly dose of either 40 i.u of oxytocin (1 ml/10 sprays) or matching placebo intranasally after a wash out period of 1 week (days 14-21). Again, the researchers and subjects will be blinded to the compound given to the subjects. Subjects will continue using their auto-CPAP during these 2 weeks as per standard-of-care. At the end of this 2 week period will be day 35, when subjects will undergo another overnight in-lab sleep study and continue to take either the placebo or oxytocin (with their auto-CPAP) to assess sleep architecture, have another venipuncture to collect 50 ml of blood, and we will download the compliance report and pressure data from their auto-CPAP. The subject and all investigators will be blinded to the sequence of oxytocin or placebo until the study is unblinded at the end of the 35 day protocol.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date November 1, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men or women 18 years of age or older. Exclusion Criteria: - subjects not willing to or otherwise unable to use CPAP for treatment of OSA. - Presence of other sleep disorders - Pregnant or breastfeeding women - Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study - Prisoners or subjects who are involuntarily incarcerated - Subjects who are compulsorily detain or treatment of either a psychiatric or physical (i.e. infectious disease) illness - Patients unable to give consent because of a language barrier, or other reason.

Study Design


Intervention

Drug:
Oxytocin
40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
Placebo
Intranasal spray to mimic Oxytocin intranasal spray

Locations

Country Name City State
United States Medical Faculty Associates Washington District of Columbia

Sponsors (2)

Lead Sponsor Collaborator
Vivek Jain George Washington University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Use of oxytocin will change pressure required to keep open airway during auto-CPAP use CPAP pressures will be monitored during study via electronic data retrieval system 5 weeks
Secondary Change in total score of self-reported daytime sleepiness using Epworth Sleepiness Scale Sleep satisfaction will be self-recorded on Epworth Sleepiness Scale (ESS). Range from 0 equal to lowest sleepiness during day and 24 equal to highest sleepiness during day. 5 weeks
Secondary Change in total score of self-reported sleep quality on Pittsburgh Quality Index Range is from 0-21 with 0 equal to better sleep quality and 21 meaning worst sleep quality. 5 weeks
Secondary Change in total score for sleep quality with Post Polysomnogram Sleep Assessment Sleep quality will be recorded from range 5 to 30 total score, 5 equal to worst sleep quality and 30 equal to best sleep quality. 5 weeks
See also
  Status Clinical Trial Phase
Completed NCT05582070 - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction N/A
Recruiting NCT03919955 - A Novel Pharmacological Therapy for Obstructive Sleep Apnea Phase 2
Completed NCT03927547 - Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders N/A
Recruiting NCT04007380 - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI N/A
Completed NCT02188498 - Electrocardiography Data Analysis in Sleep Disorders
Completed NCT01503164 - Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism N/A
Recruiting NCT00747890 - Surgical Treatment of Mild Obstructive Sleep Apnea N/A
Active, not recruiting NCT00738179 - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease Phase 3
Completed NCT00841906 - Alice PDx User/Validation Extended Trial N/A
Completed NCT00202501 - Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome N/A
Completed NCT00047463 - Effects of Treating Obstructive Sleep Apnea in Epilepsy Phase 2
Not yet recruiting NCT06029881 - Portable System for Non-intrusive Monitoring of Sleep
Recruiting NCT06093347 - Central Apnoea Monitor Study
Terminated NCT05445869 - Severe OSA Study (SOS) N/A
Withdrawn NCT04096261 - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Recruiting NCT04575740 - Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea N/A
Completed NCT04676191 - Validation of a Contactless Vital Signs Measurement Sensor N/A
Recruiting NCT06015620 - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed NCT06051097 - Metabolic Syndrome and Obstructive Sleep Apnea
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury